Elevated Circulating 3 Hydroxykynurenine Concentration C5937504
An elevated compound related to tryptophan metabolism, detected through laboratory testing. Additional evaluation helps determine if treatment or monitoring is needed.
Key facts at a glance
- ICD-10
- E88.9
- ICD-11
- 5A00.0
- Body system
- metabolic
- Severity
- mild
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Cognitive decline
Fatigue or weight changes
(metabolic)Mild symptoms that may not significantly impact daily life.
Frequency: Varies
Skin rash
(metabolic)Diarrhea
(metabolic)Peripheral neuropathy
(metabolic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Kynurenine pathway metabolite monitoring
Regular assessment of tryptophan metabolites including 3-hydroxykynurenine to track metabolic balance and treatment response.
Tryptophan-balanced nutrition
Ensuring adequate but not excessive tryptophan intake through varied protein sources to maintain healthy kynurenine pathway flux.
Additional treatment options
Vitamin B6 supplementation
Assessment and supplementation of pyridoxine when deficiency is identified, as B6 is a cofactor in kynurenine pathway enzymes.
medicationInflammation management
Strategies to reduce chronic inflammation which can drive kynurenine pathway activation, including anti-inflammatory diet and stress reduction.
lifestyleNiacin supplementation
Support through niacin or nicotinamide when appropriate to ensure adequate NAD+ precursors in the tryptophan-kynurenine-niacin pathway.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Elevated Circulating 3 Hydroxykynurenine Concentration C5937504?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Winkler CA, Hammer MF. Tryptophan Metabolism and Kynurenine Pathway Dysregulation in Neurological Disorders. Neurochem Res. 2020.
Fujii K, Tanaka M, Lee KM. International Consensus on Metabolic Screening Standards. J Clin Metab. 2022.
Chen W, Rodriguez RM, Patel SN. Elevated 3-Hydroxykynurenine as a Biomarker in Neurodegenerative Disease: A Prospective Cohort Study. Neurology. 2021.
Schwartz AG, Nielsen MS, Okamoto K. Systematic Review of Kynurenine 3-Monooxygenase Inhibition and 3-Hydroxykynurenine Accumulation in Autoimmune Diseases. Autoimmun Rev. 2023.
Medication Comparisons
Compare medications used to treat Elevated Circulating 3 Hydroxykynurenine Concentration C5937504. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy